Document Classification

Section Type: RESULTS

Text: With 75 mg daily, CYP2C19 * 2 heterozygotes had significantly higher on-treatment platelet reactivity than did noncarriers (VASP platelet reactivity index [PRI] : mean, 70. 0 % ; 95 % CI, 66. 0 % -74. 0 %, vs 57. 5 % ; 95 % CI, 55. 1 % -59. 9 %, and VerifyNow P2Y (12) reaction units [PRU] : mean, 225. 6 ; 95 % CI, 207. 7-243. 4, vs 163. 6 ; 95 % CI, 154. 4-173. 9 ; P <. 001 for both comparisons).